Answers are grounded in this paper and cite their sources.
Observational cohort study shows high clinical tumor control in meningiomas, suggesting careful use of mf-GKRS holds risks of adverse effects.
BACKGROUND AND OBJECTIVES: Multifraction Gamma Knife Radiosurgery (mf-GKRS) was introduced in the clinical practice over the past 20 years, but limited data exist about the effective radiation tolerance for these fractionated high-dose treatments. Our current aim was to report a single-institute long-term experience adopting mf-GKRS, focusing on any potential adverse effect. METHODS: Retrospective observational cohort study on 216 perioptic and/or large (>10.0 cm 3 ) meningiomas. Radiation was delivered over 3 consecutive days with Leksell G-frame. Upfront mf-GKRS was performed in 141 meningiomas (65.3%), whereas 75 (34.7%) underwent mf-GKRS as adjuvant or salvage therapy. The median follow-up was 62.0 months (IQR 43.0-85.0). RESULTS: The baseline median tumor volume was 5.9 cm 3 (IQR 2.2-11.0), and it was >10.0 cm 3 in 65 cases (30.1%). The 5-year and 10-year clinical tumor control was 96.0% (CI 97.6%-94.4%) and 87.4% (CI 91.5%-83.3%), respectively. Cox regression demonstrated that up-front radiosurgery was the only independent predictor for better clinical tumor control ( P = .011). Clinical outcome was stable or improved in 168 patients (77.8%) and transiently worse in 48 (22.2%), but the early and late rate of adverse radio-induced events with toxicity grade 3-4 was 2.8%. The risk of cranial nerve neuropathies (12.0%) remains higher in tumors larger than 10.0 cm 3 ( P = .019), despite hypofractionation. No cases of blindness occurred after mf-GKRS but optic neuropathy, new or worsening of preexisting one, developed in 7.9% cases: pretreatment visual decline ( P = .008) and daily dose to 1 mm 3 of anterior visual pathways ≥6.7 Gy ( P = .011) were risk factors. Post-treatment edema (3.2%) was associated with higher gradient index ( P = .008). CONCLUSION: Mf-GKRS is effective and safe in perioptic meningiomas, representing a valid alternative to conventionally fractionated radiotherapy, adopting the limit of 6.7 Gy per fraction to 1 mm 3 of anterior visual pathways, whereas it could be used with caution for large skull base meningiomas.
No takes yet. Share an insight, caveat, or question.
Barzaghi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: